Skip to Main Content

4,820

Views

40

CrossRef citations to date

0

Altmetric

Original Articles

Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Luke CoyleDepartment of Haematology, Royal North Shore Hospital, St. Leonards, Australia; Correspondence[email protected]
View further author information

,

Nicholas J. MorleyDepartment of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; View further author information

,

Alessandro RambaldiDepartment of Oncology-Hematology, University of Milan and Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; View further author information

,

Kylie D. MasonDepartment of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia; View further author information

,

Gregor VerhoefDepartment of Hematology, UZ Leuven, University Hospitals Leuven, Leuven, Belgium; View further author information

,

Caroline L. FurnessDepartment of Paediatric Haemato-Oncology, Royal Marsden NHS Foundation Trust, London, UK; View further author information

,

Alicia ZhangGlobal Biostatistical Science, Amgen Inc, Thousand Oaks, CA, USA; View further author information

,

A. Scott JungGlobal Development, Amgen Inc, Thousand Oaks, CA, USAView further author information

,

David CohanGlobal Development, Amgen Inc, Thousand Oaks, CA, USAView further author information

&

Janet L. FranklinGlobal Development, Amgen Inc, Thousand Oaks, CA, USAView further author information